Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 11/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 11/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7467442 | 0.93 | KMT2A (0.49) | ITGB1ITGA4KMT2ANPC1CTSD | |
| SCHEMBL7219807 | 0.89 | ITGB1 (0.54) | ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL7459141 | 0.84 | NPC1 (0.41) | ITGB1ITGA4KMT2ANPC1RAB9A | |
| SCHEMBL7464392 | 0.84 | NPC1 (0.41) | ITGB1ITGA4KMT2ANPC1RAB9A | |
| SCHEMBL7468356 | 0.84 | KMT2A (0.45) | ITGB1ITGA4KMT2ARAB9A | |
| SCHEMBL7461109 | 0.83 | KMT2A (0.45) | ITGB1ITGA4KMT2ARAB9ATP53 | |
| SCHEMBL7467339 | 0.83 | KMT2A (0.45) | ITGB1ITGA4KMT2ARAB9ATP53 | |
| SCHEMBL7464096 | 0.83 | NPC1 (0.43) | ITGB1ITGA4KMT2AP2RX7NPC1 | |
| SCHEMBL7462350 | 0.83 | NPC1 (0.43) | ITGB1ITGA4KMT2AP2RX7NPC1 | |
| SCHEMBL7462016 | 0.82 | KMT2A (0.49) | ITGB1ITGA4KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |